Daily Market Reports | 10:30 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
29M ANZ BGL (2) BM1 (2) CAT (2) CBA DUG IPH MYX NAB NEU RDY REG WBC
NEU NEUREN PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $22.11
Canaccord Genuity rates ((NEU)) as Buy (1) -
Canaccord Genuity maintains a Buy rating for Neuren Pharmaceuticals with a $25.90 target price following Acadia Pharmaceuticals signing an exclusive distribution agreement with KYORIN Pharmaceutical for DAYBUE STIX in Japan.
Following positive Phase III Japanese clinical trial results announced in November, regulatory filing in Japan is planned for 2027 ahead of a potential commercial launch in 2028, entitling Neuren Pharmaceuticals to US$15m upon first commercial sale, up to US$110m in sales milestones, and tiered mid-teens to low-20s royalties.
Japan is excluded from Canaccord's explicit forecasts aside from the US$15m first sales milestone projected in the second quarter of 2028, leaving upside potential beyond Canaccord's rest-of-world peak DAYBUE sales estimate of US$250m and US peak sales estimate of US$660m.
Canaccord views Kyorin's appointment as further de-risking the commercial pathway, citing Kyorin's established Japanese distribution infrastructure and recent licensing expansion into rare and central nervous system diseases.
Canaccord derives its $25.90 sum-of-the-parts valuation from DAYBUE at $17.15 per share alongside NNZ-2591 in Phelan-McDermid, Pitt Hopkins, and SYNGAP-1 disorders at $5.22, $2.69, and $0.84 per share, while noting clinical trial, gastrointestinal compliance, competitive, and regulatory risks.
This report was published on November 17, 2026.
Target price is $25.90 Current Price is $22.11 Difference: $3.79
If NEU meets the Canaccord Genuity target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $26.77, suggesting upside of 21.1%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 42.5, implying annual growth of 79.1%.
Current consensus DPS estimate is 33.0, implying a prospective dividend yield of 1.5%.
Current consensus EPS estimate suggests the PER is 52.0.
Forecast for FY27:
Current consensus EPS estimate is 55.4, implying annual growth of 30.4%.
Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 39.9.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
RDY READYTECH HOLDINGS LIMITED
Software & Services - Overnight Price: $1.36
Shaw and Partners rates ((RDY)) as Buy (1) -
Shaw and Partners reiterates its Buy rating for ReadyTech Holdings with its target price increased to $2.90 from $2.80 following an agreement to divest the non-core Managed Payroll Services business to Group Elephant for $7m in cash.
Completion is expected by the end of 1H FY27 alongside transitional services running until 30 June 2027, with sale proceeds funding an on-market share buyback of up to $5m and any remainder directed towards debt reduction and general corporate purposes.
Underlying FY27 guidance is reaffirmed with cash EBITDA margins held at 15% to 17% while revised revenue guidance of $120m to $124m excludes the divested unit, driving a -3% reduction in Shaw's FY27 revenue forecast to $126m and a -3% cut to EBITDA to $37.3m.
Shaw views the divestment positively as it removes a source of elevated customer churn, sharpens focus on core software platforms, and improves revenue mix, gross margins, organic growth, and capital efficiency entering FY28.
Trading on roughly 9.0x FY28 EV/cash EBITDA, the shares are considered undervalued given accelerating organic growth and operating leverage potential, with the revised $2.90 target price implying 17.4x FY28 EV/cash EBITDA.
This report was published on November 17, 2026.
Target price is $2.90 Current Price is $1.36 Difference: $1.54
If RDY meets the Shaw and Partners target it will return approximately 113% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.80 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 75.56.
Forecast for FY28:
Shaw and Partners forecasts a full year FY28 dividend of 0.00 cents and EPS of 13.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 9.93.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
REG REGIS HEALTHCARE LIMITED
Aged Care & Seniors - Overnight Price: $4.65
Jarden rates ((REG)) as Neutral (3) -
Jarden maintains a Neutral rating for Regis Healthcare with a $6.20 target price following an annual general meeting update detailing 1Q27 operational performance.
Average occupancy held steady at 95.6% in 1Q27 alongside a 7% rise in average incoming full refundable accommodation deposits (RADs) to $750k after August room price increases of around 10%, while net RAD inflows softened in favour of Daily Accommodation Payments (DAPs) amid slower property market conditions.
Existing residents were transitioned to the Higher Everyday Living Fee ahead of the 1 November deadline, while refurbishment plans across 1,000 existing beds and the opening of the 123-bed Toowong greenfield facility with roughly 24% day-one occupancy support ongoing growth.
Jarden views management's swift cost response and rising DAP contributions positively for FY27 earnings, though the shift away from RAD inflows is regarded as a slight negative as Jarden retains its $6.20 discounted cash flow valuation pending clearer visibility on offsetting the funding shortfall.
This report was published on November 17, 2026.
Target price is $6.20 Current Price is $4.65 Difference: $1.55
If REG meets the Jarden target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $5.88, suggesting upside of 26.5%(ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 18.4, implying annual growth of -0.2%.
Current consensus DPS estimate is 19.2, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 25.3.
Forecast for FY28:
Current consensus EPS estimate is 23.0, implying annual growth of 25.0%.
Current consensus DPS estimate is 24.0, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 20.2.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WBC WESTPAC BANKING CORPORATION
Banks - Overnight Price: $36.82
Jarden rates ((WBC)) as Sell (5) -
Jarden maintains a Sell rating for Westpac with a $30.00 target price following an industry review of Australian major bank credit provisioning models and risk-weight inflation sensitivity ahead of a looming credit cycle.
Westpac carries a 31% corporate loss given default assumption across a 23% corporate loan book mix, so resetting towards the 40% long-term industry average lifts modelled expected losses by 33%, or $749m, and trims excess collective provisions to $0.6bn from $1.4bn, representing 0.18% of credit risk-weighted assets.
Jarden estimates a one percentage point rise in credit risk-weight density from 28% to 29% trims common equity tier one capital by -40bps, prompting banks to consider tempering replicating portfolio hedges and tolerating short-term net interest margin volatility.
Trading on an 18.2x FY27 price-to-earnings multiple with common equity tier one capital projected at 12.3% in FY27 before easing to 12.1% in FY28 alongside 2% annual earnings per share growth, Westpac faces an expected total shareholder return of -16.6%.
Jarden derives its $30.00 target price from a blended average of dividend discount model, normalised price-to-book, and relative price-to-earnings multiples, while flagging downside risks from macroeconomic or cash rate headwinds, heightened competition, and higher technology simplification costs.
This report was published on November 16, 2026.
Target price is $30.00 Current Price is $36.82 Difference: minus $6.82 (current price is over target).
If WBC meets the Jarden target it will return approximately minus 19% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $33.60, suggesting downside of -8.7%(ex-dividends)
The company's fiscal year ends in September.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 156.00 cents and EPS of 208.00 cents.
At the last closing share price the estimated dividend yield is 4.24%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.70.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 206.6, implying annual growth of 3.7%.
Current consensus DPS estimate is 155.8, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 17.8.
Forecast for FY28:
Jarden forecasts a full year FY28 dividend of 158.00 cents and EPS of 212.00 cents.
At the last closing share price the estimated dividend yield is 4.29%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.37.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 215.0, implying annual growth of 4.1%.
Current consensus DPS estimate is 157.8, implying a prospective dividend yield of 4.3%.
Current consensus EPS estimate suggests the PER is 17.1.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
Decisions about inclusions in this Report are made independently of the providers of stock market research and at full discretion of the team of journalists responsible for content at FNArena. Inclusion does not equal endorsement, in any way, shape or form. This Report is provided for informational purposes only.
FNArena content is produced by real people. We use AI tools to assist with grammar checks, research verification and internal processes. Our experienced editorial team follows financial markets closely, identifies valuable insights from research reports and retains full responsibility for editorial decisions and published content.
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE
